Evercore ISI Group analyst Steve Sakwa maintains UDR (NYSE:UDR) with a In-Line and lowers the price target from $51 to $49.
Evercore ISI Group Maintains In-Line on UDR, Lowers Price Target to $49
Evercore ISI Group analyst Steve Sakwa maintains UDR (NYSE:UDR) with a In-Line and lowers the price target from $51 to $49.
Related Posts
Market Volatility Declines Sharply After Nasdaq Jumps More Than 300 Points
U.S. stocks rose sharply on Wednesday, with Treasury yields climbing to two-week highs on Wednesday following better-than-expected economic data and strong projections from some major companies.
All the three major indices settled higher, with Nasdaq settling at a three-month high level on Wednesday.
Where Ascendis Pharma Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Stephens & Co. Upgrades AZEK Co to Overweight, Lowers Price Target to $41
Stephens & Co. analyst Trey Grooms upgrades AZEK Co (NYSE:AZEK) from Equal-Weight to Overweight and lowers the price target from $47 to $41.